Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO

Journal of Clinical Epidemiology

Volumn 54, Issue 10, 2001, Pages 1056-1064

  Reynolds, Robert F ^a   Walker, Alexander M ^b   Obermeyer, Carla Makhlouf ^b   Rahman, Omar ^b   Guilbert, Daniel ^c  

^a PFIZER INC   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Fallon Clinic   (United States)

Author keywords

Estrogen therapy; HMO; Hormone therapy; Menopause; Patient compliance

Indexed keywords

CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MONOAMINE OXIDASE INHIBITOR; PIPERAZINE ESTRONE SULFATE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0034819899     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(01)00378-X     Document Type: Article

References (60)

1. Hormone therapy to prevent disease and prolong life in postmenopausal women
2. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women
3. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
4. Hormone replacement therapy
5. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
6. Hormone replacement therapy and peripheral arterial disease
7. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT)
8. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women
9. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration
10. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
11. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
12. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
13. Commentary on the Women's Health Initiative
14. Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
15. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
16. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women
17. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
18. Risk of venous thromboembolism in users of hormone replacement therapy
19. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
20. Prospective study of exogenous hormones and risk of pulmonary embolism in women
21. Decision-making and hormone replacement therapy; a qualitative analysis
22. Women and menopause; beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey
23. Women's reasons for using postmenopausal hormone replacement therapy; preventative medicine or therapeutic aid?
24. Women's beliefs and decisions about hormone replacement therapy
25. HRT prescribing guidelines
26. Prevalence, initiation, and continuation of hormone replacement therapy
27. Continuation of postmenopausal hormone replacement therapy; comparison of cyclic versus continuous combined schedules
28. Hormone use among middle-aged women; results of a three-year study
29. Compliance of women in taking estrogen replacement therapy
30. The prevalence of oestrogen replacement therapy in South Australia
31. What women want from hormone replacement therapy; results of an international study
32. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis
33. Patient noncompliance with hormone replacement therapy; a nationwide estimate using a large prescription claims database
34. Characteristics of women who continue using hormone replacement therapy
35. Compliance with hormone therapy
36. Compliance with hormonal replacement therapy
37. Compliance considerations with estrogen replacement; withdrawal bleeding and other factors
38. Attitudes toward menopause and hormone therapy among women with access to health care
39. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women
40. Use of postmenopausal hormone replacement therapy; estimates from a nationally representative cohort study
41. Comparison of continuation of postmenopausal hormone replacement therapy; transdermal versus oral estrogen
42. Risk factors associated with women's compliance with estrogen replacement therapy
43. Side-effects and socio-behavioral factors associated with the discontinuation of hormone therapy in a Massachusetts HMO
44. Discrete-time methods for the analysis of event histories
45. The North American Menopause Society 1998 menopause survey; Part II. Counseling about hormone replacement therapy: association with socioeconomic status and access to medical care
46. Prevalence of and factors associated with hormone replacement therapy counseling; results from the 1994 National Health Interview Survey
47. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy
48. Provider attitudes and self-reported behaviors related to hormone replacement therapy
49. Estrogen replacement therapy; a survey of women's knowledge and attitudes
50. Hrt; the woman's perspective
51. Relationship between estrogen, serotonin, and depression
52. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial
53. The role of serotonin in hot flushes
54. Recent patterns of hormone replacement therapy use in a large managed care organization
55. Achieving long-term continuance of menopausal ERT/HRT; consensus opinion of the North American Menopause Society